Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone HCl ER in pediatric chronic pain
NCT02321319Phase 3Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Mar 2017
- Primary completion
- Feb 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydromorphone in chronic pain, sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events at 28 days. Started Mar 2017; status: terminated.
02
Drugs
hydromorphone
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT02321319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02321319.